Related content

Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2⁺ patients with hormone-refractory prostate cancer

By Matsueda Satoko   Kobayashi Kazuhiko   Nonaka Yoichi   Noguchi Masanori   Itoh Kyogo   Harada Mamoru  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 6, 2004-06 ,pp. : 479-489

Springer Publishing Company

Access to resources Recommend Favorite

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

By Wobser Marion   Keikavoussi Petra   Kunzmann Volker   Weininger Markus   Andersen Mads   Becker Juergen  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 10, 2006-10 ,pp. : 1294-1298

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer

By                    

Experimental and Therapeutic Medicine, Vol. 2, Iss. 1, 2011-01 ,pp. : 109-117

Spandidos Publications

Access to resources Recommend Favorite

Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 17, Iss. 6, 2017-06 ,pp. : 851-858

Bentham Science Publishers

Access to resources Recommend Favorite

Two novel squamous cell carcinoma antigen-derived HLA-A*0201-binding peptides induce in vitro and in vivo CD8+ cytotoxic T lymphocyte responses

By                  

International Journal of Oncology, Vol. 42, Iss. 4, 2013-01 ,pp. : 1482-1492

Spandidos Publications

Access to resources Recommend Favorite